Legal Representation
Attorney
Scott D. Woldow
USPTO Deadlines
Next Deadline
1970 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2024-12-03)
Due Date
December 03, 2030
Grace Period Ends
June 03, 2031
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
19 events| Date | Code | Type | Description |
|---|---|---|---|
| Dec 3, 2024 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED |
| Dec 3, 2024 | R.PR | A | REGISTERED-PRINCIPAL REGISTER |
| Oct 1, 2024 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Oct 1, 2024 | PUBO | A | PUBLISHED FOR OPPOSITION |
| Sep 11, 2024 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Aug 27, 2024 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Aug 27, 2024 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Aug 27, 2024 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Aug 27, 2024 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Jun 11, 2024 | RFNP | P | REFUSAL PROCESSED BY IB |
| May 15, 2024 | RFRR | P | REFUSAL PROCESSED BY MPU |
| May 15, 2024 | RFCS | P | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| May 7, 2024 | RFCR | E | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| May 6, 2024 | CNRT | R | NON-FINAL ACTION WRITTEN |
| Apr 30, 2024 | DOCK | D | ASSIGNED TO EXAMINER |
| Feb 16, 2024 | PARI | I | TEAS VOLUNTARY AMENDMENT RECEIVED |
| Oct 24, 2023 | MAFR | O | APPLICATION FILING RECEIPT MAILED |
| Oct 20, 2023 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Oct 19, 2023 | REPR | M | SN ASSIGNED FOR SECT 66A APPL FROM IB |
Detailed Classifications
Class 005
Pharmaceutical preparations for cardiovascular diseases, illnesses, and conditions; Pharmaceutical preparations for infusion conditions; pharmaceutical preparations for cardiovascular conditions and blood conditions, namely, novel, plasma derived apolipoprotein A-I conditions while undergoing infusion therapy; pharmaceutical preparations for novel apolipoprotein A-I infusion therapy to potentially reduce the risk of recurrent major adverse cardiovascular events (MACE) in patients within 90 days of an acute myocardial infarction (AMI) with a sustained benefit for 365 days; Pharmaceutical preparations for acute myocardial infarction (AMI); Pharmaceutical preparations for cardiovascular diseases; pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema, fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; Pharmaceutical preparations for the treatment and prevention of blood and bleeding disorders; pharmaceutical preparations for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of hemophilia, namely, pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia; pharmaceutical preparations and substances for the treatment of blood disorders; pharmaceutical preparations for the treatment of blood conditions, respiratory conditions, pneumonia, covid-19, and influenza; Pharmaceutical preparations, namely, antibody for the treatment of acute respiratory distress syndrome, ARDS; pharmaceutical preparations, namely, antibody for the treatment of Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD; Pharmaceutical preparations, namely, antibody for the treatment of Hereditary Angioedema, HAE; Pharmaceutical preparations, namely, for the treatment of Hereditary Angioedema, HAE, respiratory diseases, acute respiratory distress syndrome, ARDS, Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD
Classification
International Classes
005